Citeline

Stay ahead of FDA shifts that could impact your strategy. vist.ly/4yi8m The landscape of drug approvals is evolving under new leadership and changing regulations. Save time and focus on what matters—accelerating life-saving therapies. Download our latest eBook now!

The long-range pipeline count shows a rare moment: 22,940 drugs in active R&D at the start of 2026 — down 3.92% vs. last year. Harvest the full story behind the shift — download the report. vist.ly/4yfdk

Countdown to compliance has begun. The UK’s updated clinical trial transparency requirements take effect 28 April, with significant implications for trial registration, results publication, and deferrals. 📌 Watch to understand: vist.ly/4yayz

How is AI shaping the future of medtech? vist.ly/4y7fi 
Check out our new infographic for headline stats, expert insights, and a global perspective on regulations and challenges.
Get a first look at the trends driving smarter, more personalized healthcare!

When every patient is rare, the difference isn't just speed — it’s precision. vist.ly/4xzuw Discover how Citeline PatientMatch can propel qualified patients into your recruitment pipeline.

Citeline has been named a winner in @Global_H_Pharma Magazine's Biotechnology & Lifesciences Awards 2026. We are proud to be recognized as one of the Best AI-Powered Clinical Research Data Solutions. vist.ly/4xz8v

What if you had real-time insights into biopharma's future? With The In Vivo Report, you do. vist.ly/4xwcj Access crucial data, connect with industry decision-makers, and stay ahead of the competition. Elevate your strategy and make informed decisions that save lives.

The long-range pipeline count shows a rare moment: 22,940 drugs in active R&D at the start of 2026 — down 3.92% vs. last year. Harvest the full story behind the shift — download the report. vist.ly/4xwcf

Looking for in-depth coverage of China’s biopharma industry? vist.ly/4xuxq Our comprehensive eBook covers market-defining trends, top deals, and actionable strategies for financial professionals.

At #SwissBiotechDay 2026, Citeline will host a panel on what’s next in R&D, innovation, and clinical development, exploring how emerging trends are reshaping the industry. Plan ahead and book a meeting with us: vist.ly/4xrua

The number of drugs in development has fallen for the first time since the 1990s. Is this just a blip or the start of a trend? An article in @FiercePharma and @FierceBiotech featured key findings from Citeline’s Pharma R&D Annual Review 2026. vist.ly/4xq63

It’s never been more important to incorporate diversity and representation in your clinical trials. Discover how we can broaden your patient recruitment reach: vist.ly/4xgtg

Our datasets pulse with the purpose of educating, engaging, and enrolling the precise patients you need for your clinical trials. Discover the new era of patient recruitment: vist.ly/4xbi2

In rare disease trials, every match can change the outcome. With AI‑powered prescreening, sponsors are finding qualified patients faster — and with more precision. In just one week, Citeline PatientMatch generated 398 actionable alerts, identifying 20% of all randomized U.S. patients for this study. Discover how Citeline PatientMatch can propel qualified patients into your recruitment pipeline. 🔗 vist.ly/4xa2w 💬 What’s the biggest barrier you see today in connecting rare patients to the right trials? ———— Follow @Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

AI is transforming patient care and product innovation in medtech - are you keeping up? vist.ly/4x8yn 
Our latest eBook from Medtech Insight covers $9.2B in AI-enabled device deals, strategies for embracing AI-driven care, and insights from industry leaders.

A @Bloomberg column on how generic Ozempic is a game changer for China and India cited data from Citeline. The column notes that the simultaneous patent expiry of Ozempic’s active ingredient in China and India is a watershed moment.. Now, the entry of affordable generic versions will be a leveling force in healthcare. The world’s two most-populous countries are home to pharmaceutical companies capable of exploiting this to reshape the market for metabolic therapies.

The market for KRAS-targeting oncology drugs could be poised to boom in the next few years. | vist.ly/4x7kf In a @PharmaVoice article on the KRAS space, Citeline analyst Neha Anand weighed in on the market performance of KRAS drugs like Amgen’s Lumakras and outlined how the next wave of KRAS therapies in the pipeline is taking shape. What do you think will be the biggest opportunity in this emerging market?

Asia’s Biopharma Revolution: vist.ly/4x4td China leads the world in new drug development. Korea and Japan are striking billion-dollar deals. India is stepping into innovation with first-in-class breakthroughs. The Scrip Asia 100 report reveals the top 100 pharma companies in Asia by sales – plus the trends, data, and deals shaping the future of global pharma. 🔍 Want to know what’s driving the shift east? Access the report: vist.ly/4x4td #ScripAsia100 #NewsAndInsights _____ Follow @Citeline News & Insights for in-depth journalism and analysis of the pharma, biotech, medtech, and consumer health industries. Start your 7-day free trial today: vist.ly/4x4tf

The conversation continues with Series 2 of #SmallBiotechsBigDecisions — Claire Riches, in conversation with four expert voices. Coming soon. Explore more: vist.ly/4w22d

Blooming, or withering on the vine? 🌱 In today’s R&D landscape, pipeline success is far from guaranteed and the cost of getting it wrong continues to rise. Join Citeline at #SwissBiotechDay 2026 in Basel at booth 34 where we’ll connect with biotech and pharma leaders to explore the trends shaping R&D, clinical development, and innovation. Plan ahead and book your meeting with us: vist.ly/4wy3x ----- Follow @Citeline and stay at the forefront of clinical trial innovation. We connect patients, caregivers, physicians, and partners with cutting-edge technology and data-driven solutions to simplify enrollment and accelerate life-changing treatments worldwide.